Biomea Fusion Inc (BMEA NASDAQ) stock market data APIs
$1.4132
-0.03(-2.1%)
as of October 9, 2026
Try our APIs with
free plan!
Biomea Fusion Inc Financial Data Overview
Price chart is built with
Anychart
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.
Prev. Close
1.4132
Open
1.3878
High
1.4518
Low
1.3688
52 wk Range
0.8719-2.237
Market Cap
103 M
Shares Outstanding
72 299 K
EPS
-0.12
Beta
-0.298
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Biomea Fusion Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Biomea Fusion Inc data using free add-ons & libraries
Get Biomea Fusion Inc Fundamental Data
Biomea Fusion Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -55 319 000
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-05
- EPS/Forecast: -0.21
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Biomea Fusion Inc News
New
Biomea slips after halting stock offering, delaying trial readout
[Red dollar sign pointing down with arrow, concept of financial loss, market decline and recession, 3d render] Shares of Biomea Fusion (BMEA [https://seekingalpha.com/symbol/BMEA]) fell on Wednesday ...
Biomea Fusion to Participate in Upcoming Investor Conferences
Biomea Fusion, Inc. SAN CARLOS, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Company" or "Company management") (Nasdaq: BMEA), a clinical-stage diabetes and obesity co...
Sector Update: Healthcare Stocks Softer Late Afternoon
Healthcare stocks decreased late Monday afternoon, with the NYSE Healthcare Index and the State Stre PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Citi Predicts Up to 410% Rally for These 2 ‘Strong Buy’ Stocks
With the third quarter well underway and most second-quarter earnings now in the rearview mirror, investors are starting to look ahead to the rest of 2026 and how best to position their portfolios. S...
Get Biomea Fusion Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.